标题
Pharmacogenomics toward personalized tamoxifen therapy for breast cancer
作者
关键词
-
出版物
PHARMACOGENOMICS
Volume 16, Issue 3, Pages 287-296
出版商
Future Medicine Ltd
发表日期
2015-02-25
DOI
10.2217/pgs.14.171
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype
- (2014) Eduardo Martinez de Dueñas et al. BREAST
- FDA Approval of Paroxetine for Menopausal Hot Flushes
- (2014) Ronald J. Orleans et al. NEW ENGLAND JOURNAL OF MEDICINE
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
- (2013) M A Province et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies
- (2013) Kazuma Kiyotani et al. JOURNAL OF HUMAN GENETICS
- Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004–2010
- (2012) Stacie B. Dusetzina et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
- (2012) Solai Elango Damodaran et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- (2012) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Y. Nakamura et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Tamoxifen and CYP2D6: A Contradiction of Data
- (2012) D. L. Hertz et al. ONCOLOGIST
- The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
- (2011) L. K. Teh et al. AAPS Journal
- Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
- (2011) Kazuma Kiyotani et al. BREAST CANCER RESEARCH AND TREATMENT
- Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment
- (2011) In Hae Park et al. BREAST CANCER RESEARCH AND TREATMENT
- Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
- (2011) T E Mürdter et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
- (2011) L Madlensky et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
- (2011) Hitoshi Zembutsu et al. Expert Review of Anticancer Therapy
- A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese
- (2011) Kazuma Kiyotani et al. HUMAN MOLECULAR GENETICS
- Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
- (2011) William J. Irvin et al. JOURNAL OF CLINICAL ONCOLOGY
- Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment
- (2011) Hyung Seok Park et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark
- (2011) T. L. Lash et al. JNCI-Journal of the National Cancer Institute
- Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
- (2010) Jennifer Gjerde et al. BMC CANCER
- Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen
- (2010) Nava Siegelmann-Danieli et al. BREAST CANCER RESEARCH AND TREATMENT
- Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy
- (2010) Alastair M. Thompson et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact ofCYP2D6*4genotype on progression free survival in tamoxifen breast cancer treatment
- (2010) Julia Carolin Stingl et al. CURRENT MEDICAL RESEARCH AND OPINION
- Evidence and Practice Regarding the Role for CYP2D6 Inhibition in Decisions About Tamoxifen Therapy
- (2010) Timothy L. Lash et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer
- (2010) Vincent O. Dezentjé et al. JOURNAL OF CLINICAL ONCOLOGY
- Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
- (2010) Kostandinos Sideras et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- Managing menopausal symptoms and depression in tamoxifen users: Implications of drug and medicinal interactions
- (2010) Julie Eve Desmarais et al. MATURITAS
- Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response
- (2010) Kazuma Kiyotani et al. Pharmacogenetics and Genomics
- CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance
- (2010) Michaela J. Higgins et al. Current Oncology Reports
- Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
- (2009) T. Ramón y Cajal et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
- (2009) Masatsugu Okishiro et al. CANCER
- No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications
- (2009) T. P. Ahern et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- CYP2D6 Genotyping for Functional-Gene Dosage Analysis by Allele Copy Number Detection
- (2009) N. Hosono et al. CLINICAL CHEMISTRY
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
- (2008) Y. Xu et al. ANNALS OF ONCOLOGY
- Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy
- (2008) Kazuma Kiyotani et al. CANCER SCIENCE
- Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients
- (2008) W. G. Newman et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now